Peneliti     Keyword     Tahun

Kedokteran | Kedokteran Gigi | Hukum | Ekonomi & Bisnis | Farmasi | Kedokteran Hewan | I Sosial & I Politik | Fakultas Sains dan Teknologi | Kesehatan Masyarakat | Psikologi | Ilmu Budaya | Keperawatan | Perikanan dan Kelautan |

Pengabdian Kepada Masyarakat

Prof. Dr. H. Askandar Tjokroprawiro, dr.,Sp.PD, K-EMD

diabetes@rad.net.id

Fakultas Kedokteran / Departemen Ilmu Penyakit Dalam

Tim Peneliti :

  1. Askandar Tjokroprawiro --> Peneliti Utama

Tahun : 2012

Halaman Naskah : 8 halaman

Sumber Dana : Mandiri

Besaran Dana : 1000000

SK. Penetapan :

Publikasi : Seminar : Pertemuan Ilmiah Berkala XII Ilmu Penyakit Dalam 2012

Kategori Penelitian : Kesehatan

Posting : 23-02-2012

Visitor : 1978


Download Article : PDF 4306 byte.


Title :

Inlacin®, the Novel Insulin Sensitizer in Clinical Practice (Its Roles on Mono–and Add–on Therapy for Patients with Diabetes)

Author : Prof. Dr. H. Askandar Tjokroprawiro, dr.,Sp.PD, K-EMD


Year : 2012

Abstact :

Based on clinical experiences in daily practice, oral anti diabetes (OAD) can be categorized into 6 groups in which they can be briefly described below.

  1. Insulin Secretagogues: Sulphonylureas (Gen I, II, III: Glimepiride),

Non-Sulphonylureas (Metaglinides) : Nateglinide, Repaglinide (Dexanorm®)

  1. Insulin Sensitizers:

A. Thiazolidinediones (TZDs): Glitazone Class (Pioglitazone, Netoglitazone, Darglitazone)

B. Non-TZDs:

                                      i.      Glitazar Class (Muraglitazar, Ragaglitazar, Imaglitazar, Tesaglitazar = MRIT); Muraglitazar has been withdrawn  

                                    ii.      Non-Glitazar Class (Metaglidasen: Non Edema and Non Weight Gain)

C. Biguanide: Metformin XR (Glucophage® XR), 3-Guanidinopropionic-Acid

D. DLBS-3233 (INLACIN®)

  1. Intestinal Enzyme Inhibitors: a-Glucosidase Inhibitor (Acarbose), a-Amylase Inhibitor (Tendamistase)
  2. Incretin-Enhancers DPP-4 Inhibitors: (Sitagliptin, Vildagliptin, Saxagliptin, Alo gliptin, Denagliptin, Dutogliptin, Linagliptin, Melogliptin, Teneligliptin, SYR-322, TA-666)
  3. Fixed Dose Combination Types: Glucovance®, Amaryl-M®, Galvusmet®, Janumet®, ACTOplusmet®, Duet act®
  4. Other Specific Types: Sodium GLucose co Transporter-2 (SGLT2)-Inhibitors: ASP1941, BI 10773, Canagliflozin, Dapagliflozin, Seragliflozin, Remogliflozin, AVE-2268, KGT-1681, LX-4211, TS-033, YM-543; Glucokinase Activator (GKA): MTBL1, MK-0941; OXPHOS-blocker; FBPase-Inhibitor, INCB13739 (IIβHSD7-inhibitor).

Thiazolidinediones (TZDs) such as pioglitazone, and biguanide (metformin) have been available in Indonesia for years. However, inlacin® (DBLS-3233), the novel sensitizer, has been recently launched and available in the first months of this year (2011), and this OAD can be located on the number 4 of the insulin sensitizer group.


Keyword : TZDs, OAD,


List Article :

Related Article :

Visit Artikel : 22.702.499

Visit Website : 19.389.853

Google Scholar